Analyst Insights

William Blair Reiterates Outperform On Fastenal Despite Q2 Revenue Miss

In a research note released Friday, William Blair analyst Ryan Merkel reiterated an Outperform rating on Fastenal Company (FAST), despite gross margin decline in 2Q:14. Merkel …

Deere & Company: Next Year Could Be A Tough Year, Says William Blair

In a research note issued Friday, William Blair analyst Lawrence De Maria reaffirmed an Underperform rating on Deere & Company (DE) with a $80 price target, which suggests …

Salesforce Continues To Be Our Favorite Large-Cap Growth Name, Says Canaccord

In a research report released Friday, Canaccord Genuity analyst Richard Davis reiterated a Buy rating on Salesforce.com (CRM) with a $65 price target …

William Blair Maintains Outperform On Amazon Following Significant Acceleration Of Sales In June

In a research report released Friday, William Blair analyst Mark Miller maintained an Outperform rating on Amazon (AMZN), following AMZN’s June sales trends which …

Roth Capital Maintains Neutral On Quiksilver Following New Licensing Agreements

In a research note released yesterday, Roth Capital analyst Dave King maintained coverage with a Neutral rating on shares of Quiksilver Inc. (ZQK) and a $4 price target, following yesterday’s …

Topeka Capital Reiterates Buy On Google Ahead Of 2Q14 Earnings Report

In a research note released this morning, Topeka Capital analyst Victor Anthony reiterated a Buy rating on Google (GOOG) with a $657 price target. This …

Under Armour: William Blair Sees Another Upside Revenue Surprise in Second Quarter

In a research note released yesterday, William Blair analyst Sharon Zackfia reaffirmed an Outperform rating on Under Armor Inc. (UA), as she expects UA to meet or …

William Blair Downgrades Tractor Supply To Market Perform Following A Weak Second Quarter

In a research note published yesterday, William Blair analyst Mark Miller downgraded Tractor Supply Company (TSCO) to a Market Perform rating, based on concerns that …

Janney Capital Reiterates Sell On Sarepta On FDA Concerns; Sees %50 downside

In a research report issued yesterday, Janney Capital analyst Kimberly Lee reiterated a Sell rating on Sarepta Therapeutics (SRPT) with a $13 fair value, following data release from …

Select Comfort: We See Limited Visibility For A Material Turnaround, Says Wedbush

In a research report released yesterday, Wedbush analyst Joan Storms maintained a Neutral rating on Select Comfort (SCSS) with a $17 price target, …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts